Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Debt (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Non-Current Debt for 6 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt changed 0.15% to $10.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2025, changed 0.15% year-over-year, with the annual reading at $10.9 million for FY2025, 0.17% changed from the prior year.
  • Non-Current Debt for Q4 2025 was $10.0 million at Aytu Biopharma, down from $10.4 million in the prior quarter.
  • The five-year high for Non-Current Debt was $15.0 million in Q4 2023, with the low at $129000.0 in Q4 2021.
  • Average Non-Current Debt over 5 years is $10.3 million, with a median of $10.9 million recorded in 2024.
  • The sharpest move saw Non-Current Debt tumbled 98.7% in 2021, then skyrocketed 11165.89% in 2022.
  • Over 5 years, Non-Current Debt stood at $129000.0 in 2021, then surged by 11165.89% to $14.5 million in 2022, then rose by 3.06% to $15.0 million in 2023, then tumbled by 33.35% to $10.0 million in 2024, then rose by 0.15% to $10.0 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $10.0 million, $10.4 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.